Article
Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD.
Blood - 14 Dec 2023
Leiding Jennifer W, Arnold Danielle E, Parikh Suhag, Logan Brent, Marsh Rebecca A, Griffith Linda M, Wu Ruizhe, Kidd Sharon, Mallhi Kanwaldeep, Chellapandian Deepak, Si Lim Stephanie J, Grunebaum Eyal, Falcone E Liana, Murguia-Favela Luis, Grossman Debbi, Prasad Vinod K, Heimall Jennifer R, Touzot Fabien, Burroughs Lauri M, Bleesing Jack, Kapoor Neena, Dara Jasmeen, Williams Olatundun, Kapadia Malika, Oshrine Benjamin R, Bednarski Jeffrey J, Rayes Ahmad, Chong Hey, Cuvelier Geoffrey D E, Forbes Satter Lisa R, Martinez Caridad, Vander Lugt Mark T, Yu Lolie C, Chandrakasan Shanmuganathan, Joshi Avni, Prockop Susan E, Dávila Saldaña Blachy J, Aquino Victor, Broglie Larisa A, Ebens Christen L, Madden Lisa M, DeSantes Kenneth, Milner Jordan, Rangarajan Hemalatha G, Shah Ami J, Gillio Alfred P, Knutsen Alan P, Miller Holly K, Moore Theodore B, Graham Pamela, Bauchat Andrea, Bunin Nancy J, Teira Pierre, Petrovic Aleksandra, Chandra Sharat, Abdel-Azim Hisham, Dorsey Morna J, Birbrayer Olga, Cowan Morton J, Dvorak Christopher C, Haddad Elie, Kohn Donald B, Notarangelo Luigi D, Pai Sung-Yun, Puck Jennifer M, Pulsipher Michael A, Torgerson Troy R, Malech Harry L, Kang Elizabeth M
Abstract excerpt
Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by life-threatening infections and inflammatory conditions. Hematopoietic cell transplantation (HCT) is the definitive treatment for CGD, but questions remain regarding patient selection and impact of active disease on transplant outcomes. We performed a multi-institutional retrospective and prospective study of 391 patients with CGD...
Read the complete abstract on PubMed